Vivos Submits Application for mmRNA Oral Appliance to Treat OSA
The company also plans on submitting an application to a PDAC contractor for the mmRNA appliance to be added to the Center for Medicare and Medicaid Services’ list of approved sleep apnea appliances.
APOE4 Associated With Increased COVID-19 Infection Susceptibility, Severity
The SARS-CoV-2 infection was observed in pluripotent stem cells, as well as APOE4 and APOE3 neurons and astrocytes.
The Role of Nusinersen Treatment in Unsatisfactorily Treated SMA
Wildon Farwell, MD, MPH, shed some light on the ongoing phase 4 trial and what clinical insights might be gleaned from the data.
BELIEVE Trial: Developmental and Epileptic Encephalopathies
This Week on NeurologyLive — February 8, 2021
Here's what is coming soon to NeurologyLive.
Understanding ALS Disease Course Through Genetic Associations
The director of the Massachusetts General Hospital ALS Care Center discussed the greatest needs in ALS research and why focusing on genetics can play a big role into understanding the disease course.
Stem Cell Therapy Studies in TBI and Stroke: Bijan Nejadnik, MD
The chief medical officer at SanBio discussed how the investigational agent SB623 is being studied in TBI and stroke, with future planned studies in Alzheimer disease.
Low Percentage of Migraine Episodes Associated With Stress
Study results suggest that fewer than 10% of the more than 2000 migraine episodes analyzed were associated with increased levels of perceived stress.
Challenges to Providing Optimal Care for Obstructive Sleep Apnea Identified
Study data showed that 43% of patients with obstructive sleep apnea were referred to sleep specialist physicians for ongoing management by a primary care provider.
QRA-244 Shows Promise in Slowing ALS in Preclinical Studies
The chief scientific officer of QurAlis discussed how QRA-244 is more specific and potent than retigabine, a treatment currently in clinical studies.
Rituximab Suppresses Inflammatory Disease in MS, IND Filed for ImmCelz, Laser Ablation Safe in Focal Epilepsy
Neurology News Network for the week ending February 6, 2021.
The Therapeutic Pipeline for Parkinson Disease: Stewart Factor, DO
The director of the Parkinson’s Disease and Movement Disorder Program at Emory University School of Medicine shared his perspective on the research and development of Parkinson therapies.
NeurologyLive Friday 5 — February 5, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 5, 2021.
Final Thoughts: Improving QoL in Multiple Sclerosis
Optimistic Outlook in Treating Multiple Sclerosis
Patient Support Networks for Multiple Sclerosis
OPTIMUM Trial for Multiple Sclerosis
TRIUMPHANT-MS Trial for Multiple Sclerosis
Multiple Sclerosis Fatigue
Quality of Life Issues: Cognitive Changes with MS
Patient’s Journey of Therapies for Multiple Sclerosis
Treatment Options Available for Multiple Sclerosis
Managing Psychological Symptoms of Multiple Sclerosis
First Patient Enrolled in Ganaxolone Phase 3 Refractory Status Epilepticus Trial
The RAISE trial will examine the proportion of patients with refractory status epilepticus who experience status cessation within 30 minutes of initiation of intravenous ganaxolone.
CMSC Announces New Fall Dates & Location for its 2021 Annual Meeting
The annual meeting will now take place October 25–28, 2021 at the Rosen Shingle Creek in Orlando, Florida.
Cerebral Microhemorrhages Predict Faster Worsening on CDR-SB Score
Researchers compared CMH rates in PSEN1, PSEN2, and APP mutation carriers and noncarriers of dominantly inherited Alzheimer disease.
Areas of Need in Epilepsy Research: Barbara Jobst, MD
The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.
High Adherence With Integrated Sleep Practice-Supplied PAP Machines in Disturbed Sleep Breathing
Researchers also observed that PAP machines from ISPs were used for a longer median duration than those from DMEs.
FAME Study: Partial-Onset Seizures
Zolmitriptan Demonstrates Efficacy as Migraine Treatment in Post-Hoc Analysis
Observation of pain freedom at 30 minutes was more accurate than the observation of relief at 30 minutes in predicting pain freedom at 2 hours.
